CN109476713A - 工程改造的肉毒杆菌神经毒素 - Google Patents

工程改造的肉毒杆菌神经毒素 Download PDF

Info

Publication number
CN109476713A
CN109476713A CN201780035648.4A CN201780035648A CN109476713A CN 109476713 A CN109476713 A CN 109476713A CN 201780035648 A CN201780035648 A CN 201780035648A CN 109476713 A CN109476713 A CN 109476713A
Authority
CN
China
Prior art keywords
bont
polypeptide
seq
modified
modified bont
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780035648.4A
Other languages
English (en)
Chinese (zh)
Inventor
保罗·斯滕马克
张四才
董民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of CN109476713A publication Critical patent/CN109476713A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
CN201780035648.4A 2016-06-08 2017-06-08 工程改造的肉毒杆菌神经毒素 Pending CN109476713A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662347579P 2016-06-08 2016-06-08
US62/347,579 2016-06-08
PCT/US2017/036628 WO2017214447A1 (en) 2016-06-08 2017-06-08 Engineered botulinum neurotoxins

Publications (1)

Publication Number Publication Date
CN109476713A true CN109476713A (zh) 2019-03-15

Family

ID=59227906

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780035648.4A Pending CN109476713A (zh) 2016-06-08 2017-06-08 工程改造的肉毒杆菌神经毒素

Country Status (13)

Country Link
US (1) US11104891B2 (https=)
EP (1) EP3468985A1 (https=)
JP (2) JP7152392B2 (https=)
KR (1) KR20190025906A (https=)
CN (1) CN109476713A (https=)
AU (1) AU2017277905B2 (https=)
BR (1) BR112018075363A2 (https=)
CA (1) CA3026492A1 (https=)
EA (1) EA201892784A1 (https=)
IL (1) IL263058B2 (https=)
MX (1) MX2018015254A (https=)
SG (2) SG11201810210UA (https=)
WO (1) WO2017214447A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114369623A (zh) * 2022-01-12 2022-04-19 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用
CN114410683A (zh) * 2022-01-12 2022-04-29 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的RIM3-RNAi及其应用
WO2022179552A1 (zh) * 2021-02-26 2022-09-01 重庆誉颜制药有限公司 一种经修饰的神经毒素的单链多肽及其用途

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606666XA (en) 2012-05-30 2016-09-29 Harvard College Engineered Botulinum Neurotoxin
PT3274364T (pt) * 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
US11242515B2 (en) * 2016-05-16 2022-02-08 President And Fellows Of Harvard College Method for purification and activation of botulinum neurotoxin
EP3481852B1 (en) * 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US12098169B2 (en) 2017-09-29 2024-09-24 Children's Medical Center Corporation Enterococcus faecium neurotoxin (BoNT/EN) and derivatives thereof
TWI810228B (zh) * 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
WO2019152380A1 (en) 2018-01-30 2019-08-08 Children's Medical Center Corporation Production of botulinum neurotoxins using bacillus systems
EP3752128B1 (de) * 2018-02-16 2025-01-15 preclinics discovery GmbH Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
SE542539C2 (en) * 2018-02-26 2020-06-02 Toxotech Ab Chimeric botulinum neurotoxin heavy chain binding domain
KR20230001254A (ko) 2021-06-28 2023-01-04 (주)메디톡스 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법
KR20230001260A (ko) 2021-06-28 2023-01-04 (주)메디톡스 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법
WO2023068485A1 (ko) * 2021-10-22 2023-04-27 비피메드(주) 보툴리눔 유래 펩타이드를 포함하는 탈모개선용 조성물
WO2023089343A1 (en) * 2021-11-22 2023-05-25 Ipsen Biopharm Limited Treatment of pain
GB202206348D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
KR102728382B1 (ko) * 2022-10-12 2024-11-14 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체
WO2025065012A1 (en) * 2023-09-21 2025-03-27 The Medical College Of Wisconsin, Inc. Botulinum neurotoxin variants, constructs, compositions, and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736166A (zh) * 2012-05-30 2015-06-24 哈佛大学校长及研究员协会 工程化的肉毒神经毒素

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
PT1086702E (pt) 1994-05-09 2005-08-31 William J Binder Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
EP2366787B1 (en) * 2006-01-13 2019-12-11 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
US8273865B2 (en) 2006-03-15 2012-09-25 Allergan, Inc. Multivalent clostridial toxins
EP3270951B1 (en) * 2015-03-16 2020-09-09 California Institute of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736166A (zh) * 2012-05-30 2015-06-24 哈佛大学校长及研究员协会 工程化的肉毒神经毒素

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREAS RUMMEL ET AL: "Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept", 《PANS》 *
WANGROONGSARB P ET AL: "AFN61309", 《EBI》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022179552A1 (zh) * 2021-02-26 2022-09-01 重庆誉颜制药有限公司 一种经修饰的神经毒素的单链多肽及其用途
CN114369623A (zh) * 2022-01-12 2022-04-19 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用
CN114410683A (zh) * 2022-01-12 2022-04-29 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的RIM3-RNAi及其应用
CN114369623B (zh) * 2022-01-12 2023-07-07 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的Synaptotagmin2-RNAi及其应用
CN114410683B (zh) * 2022-01-12 2023-11-28 中国人民解放军空军军医大学 一种基于Cre-lox重组系统的RIM3-RNAi及其应用

Also Published As

Publication number Publication date
AU2017277905B2 (en) 2022-04-14
MX2018015254A (es) 2019-08-16
KR20190025906A (ko) 2019-03-12
IL263058B1 (en) 2023-07-01
AU2017277905A1 (en) 2018-12-20
WO2017214447A1 (en) 2017-12-14
BR112018075363A2 (pt) 2019-03-19
JP7152392B2 (ja) 2022-10-12
SG10201912099TA (en) 2020-02-27
IL263058B2 (en) 2023-11-01
JP2022112031A (ja) 2022-08-01
US11104891B2 (en) 2021-08-31
IL263058A (en) 2018-12-31
JP2019523015A (ja) 2019-08-22
SG11201810210UA (en) 2018-12-28
EP3468985A1 (en) 2019-04-17
CA3026492A1 (en) 2017-12-14
EA201892784A1 (ru) 2019-05-31
US20190300869A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
CN109476713A (zh) 工程改造的肉毒杆菌神经毒素
JP6839239B2 (ja) 操作されたボツリヌス神経毒素
CN109803980A (zh) 新的肉毒神经毒素及其衍生物
RU2746736C2 (ru) Сконструированный ботулинический нейротоксин
US11083776B2 (en) Protoxin-II variants and methods of use
US20210363204A1 (en) Protoxin-ii variants and methods of use
CN111499725A (zh) 结合IL-4受体α的泪脂质运载蛋白突变蛋白
US9624280B2 (en) Protoxin-II variants and methods of use
US20240216487A1 (en) Intramuscular compositions of botulinum neurotoxins
WO2022197623A1 (en) Engineered botulinum neurotoxin a protease domain with improved efficacy
WO2022140249A1 (en) Improved receptor-binding domain of botulinum neurotoxin a and uses thereof
US20130225505A1 (en) Muteins of human tear lipcalin for treating neovascular disease of the anterior segment of the human eye
US20260103697A1 (en) Modified bont/a2 receptor-binding domains
WO2021006819A1 (en) Epidermal growth factor receptor (egfr) ligands
CN102695723A (zh) 改进的神经营养因子分子
US10125168B2 (en) Synthetic peptide for adjusting balance between presence of type 1 TNF receptor and type 2 TNF receptor and use thereof
HK40034619A (en) Tear lipocalin muteins binding il-4 r alpha
HK1232549B (zh) 结合IL-4受体α的泪脂质运载蛋白突变蛋白

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination